ข่าวประชาสัมพันธ์ the sanofi

FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine

If approved, Pentacel vaccine would be the first pediatric combination vaccine in the U.S. to immunize against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib) Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY; EURONEXT: SAN), is pleased that the members of an advisory committee to the U.S. Food and Drug Administration (FDA) voted nearly unanimously today that the company's pentavalent combination vaccine for use in pediatric patients is

sanofi pasteur Influenza Vaccine Production Tops 170 Million Doses in 2006

Record Production Capabilities Strengthen sanofi pasteur's Global Leadership in the Fight Against Seasonal Influenza and Place the Company at the Forefront of Pandemic Readiness sanofi pasteur, the vaccines business of the...

SANOFI PASTEUR BROADENS PANDEMIC PREPAREDNESS WITH FIRST CLINICAL TRIAL OF NOVEL CELL BASED H7N1 VACCINE

Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first...